N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over72 hours in metastatic gastrointestinal adenocarcinoma

Background: We have reported that N-(phosphonacetyl)-L-aspartic acid (PALA) 1266 mg/m(2) can safely be given 24 hours prior to the start of a 72-hour infusion of fluorouracil (FUra) and leucovorin (LV) at doses of 2000 and 50 0 mg/m(2)/day. Since inhibition of aspartate carbamoyltransferase (ACTase) activity was evident 4 hours post PALA, we wished to evaluate PALA given 1 hour prior to FUra. Further, we studied the toxicity and pharmacokinetics w ith FUra given by either fixed-or variable-rate infusion. Patients and methods: Twenty-seven patients with gastrointestinal tract ade nocarcinomas were treated with PALA 1266 mg/m(2)/15 min followed by a 72-ho ur infusion of FUra and LV (1750 & 500 mg/m(2)/day) given by fixed- or vari able-rate (peak at 4:00 A.M.). Results: Clinical toxicity was similar in two consecutive cycles in 17 pati ents receiving fixed- and variable-rate infusion at the same FUra dose. Ove rall, grade 3 stomatitis and hand-foot syndrome occurred in 12% and 4% pati ents receiving fixed- and in 16% and 10.5% of patients receiving variable-r ate infusions. Six of 24 evaluable patients (25%) had a partial response. T he profile of FUra plasma levels (Cp) over a 24-hour period during fixed- a nd variable-rate infusions were strikingly different, but the average Cp an d area under the concentration-time curves were comparable. ACTase activity was significantly decreased at 4 and 24 hours after PALA (12% and 18% of b aseline; P < 0.001), but enzyme activity had recovered to 40% by 72 hours. Conclusions: This regimen was active and well tolerated with similar toxici ties with FUra given by either fixed- or variable rate infusion. PALA 1266 mg/m(2) significantly inhibited ACTase activity for at least 24 hours.